China's Ministry of Health, Department of Medical Administration Lauds and Endorses the Association
SHANGHAI, China, Jan. 28 /Xinhua-PRNewswire-FirstCall/ -- Linkwell Corporation (OTC Bulletin Board: LWLL), a leading developer, manufacturer and distributor of healthcare related disinfectants in China, announced today that its Chairman and CEO, Mr. Xuelian Bian addressed "The Association of Chinese Nosocomial Infections Professional Committee (Nosocomial Committee) of China Hospital Society (CHS)," which is endorsed by the Department of Medical Administration of the Ministry of Health of The People's Republic to China (PRC), held in Beijing, China. Nosocomial infections are infections that result from treatment at hospitals or healthcare service facilities. Linkwell is a rapidly growing company, serving a disinfectant market in China of approximately $6.25 Billion.
The Vice President of the Department of Medical Administration of Ministry of Health of The PRC, Mr. Zhou, Jun, addressed the meeting and praised the Nosocomial Committee's accomplishments for 2007. He joined the Director of the Nosocomial Committee, Mr. Zhu, Shijun, in the opening ceremony of the China Management of Hospital Infection web portal, which will be used to coordinate hospital sanitation issues. Shanghai Likang Disinfectant Hi-tech Co. Ltd, the subsidiary of Linkwell Corporation, co-sponsored the Nosocomial Committee event.
In a speech to the Nosocomial Committee meeting, Linkwell Corporation Chairman & CEO, Mr. Bian, Xuelian, stated, "Linkwell is honored to take on more obligations for China Hospital Infection Control. In 2007 Linkwell assumed more responsibilities for setting industry standards in China's disinfectant industry and will assist in the development of China Hospital Disinfection and Sterilization standards by working with all levels of government and medical authorities in 2008 and beyond."
More than 90 senior doctors of hospital infection management from Beijing's top tier hospitals and members of the Nosocomial Committee participated in the meeting.
About Nosocomial
Nosocomial infections are infections that result from treatment at hospitals or healthcare service facilities, but secondary to the patient's original condition. Nosocomial infections have alarmed the healthcare sector in the 21st century as antibiotic resistance spreads.
Thorough hand washing and/or use of alcohol rubs by all medical personnel before each patient contact and careful use of anti-microbial agents, such as antibiotics, are vital to combating Nosocomial infections. In the United States, it has been estimated that as many as one hospital patient in ten acquires a nosocomial infection, or 2 million patients a year. Annual cost estimates for treating Nosocomial infections in the U.S. range from $4.5 billion to $11 billion and up and contributed to 88,000 deaths in the U.S. in 1995. One third of nosocomial infections are considered preventable.
About Linkwell Corporation
Linkwell Corporation develops, manufactures, and distributes disinfectant healthcare products in China through its subsidiary Shanghai Likang Disinfectant High Tech Company ("Likang"). Linkwell's disinfectant healthcare products are a nationally recognized domestic Chinese brand in this market segment. Linkwell products include disinfectants in liquid, tablet, powder and aerosol form. Through Likang, Linkwell has a national marketing and sales presence throughout all 22 provinces, 5 autonomous regions, and 4 special municipalities of China. For more info about the company, please visit http://www.linkwell.us .
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on current expectations or beliefs, including, but not limited to, statements concerning the Company's operations, financial performance and condition. For this purpose, statements that are not statements of historical fact may be deemed to be forward-looking statements. The Company cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to, the impact of competitive products, pricing and new technology; changes in consumer preferences and tastes; and effectiveness of marketing; changes in laws and regulations; fluctuations in costs of production, and other factors as those discussed in the Company's reports filed with the Securities and Exchange Commission from time to time. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
